Lupus Research

09:55 EDT 16th August 2018 | BioPortfolio

Progression of subclinical atherosclerosis in systemic lupus erythematosus versus rheumatoid arthritis: the impact of low disease activity.

The progression of subclinical atherosclerosis in SLE and RA has not been comparatively assessed. We sought to investigate the impact of low disease activity and other disease-related factors on atherosclerosis progression in SLE vs RA.

Recommendations and barriers to vaccination in systemic lupus erythematosus.

Patients with Systemic Lupus Erythematosus (SLE) pose a unique dilemma pertaining to immunization against common pathogens. SLE patients are usually not immunized with vaccines based on the fear of either precipitating infection in this immunosuppressed patient population (with live vaccines) or aggravating autoimmunity and hence lupus flares (with any vaccines). However, elevated vulnerability to...

Liver disease in systemic Lupus erythematodes - results of an explorative observational study.

 Systemic lupus erythematodes (SLE) represents an autoimmune disease with a highly variable clinical course affecting numerous organs. Hepatic manifestation seems to be rare. It is not clear whether hepatic disease in SLE is of any prognostic importance or whether it correlates with disease activity.

Reply to: "S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)".

We read with great interest the guideline for the treatment of cutaneous lupus erythematosus (CLE) elaborated by the European Dermatology Forum in cooperation with the European Academy of Dermatology and Venereology published in the Journal of the European Academy of Dermatology and Venereology in March 2017. A therapeutic guide for CLE is absolutely necessary to decide the best management of our ...

Adipokine interactions promote the pathogenesis of systemic lupus erythematosus.

Adipokines are chemical mediators released from adipose tissue involved in regulation of appetite, insulin sensitivity, immune system and inflammatory responses. Adipokines contributes to low grade inflammatory response in autoimmune disease like Systemic Lupus Erythematosus (SLE) but the pathophysiology is yet not clear. The aim of this study is to understand role of adipokine interactions in SLE...

Seronegative cat scratch disease in a patient with systemic lupus erythematosus.

Ocular Involvement in Systemic Lupus Erythematosus: The Experience of Two Tertiary Referral Centers.

To assess the prevalence of the ocular manifestations related to the disease and/or ascribable to the administration of potentially toxic drugs in a cohort of 98 patients with systemic lupus erythematosus (SLE).

White-matter integrity in patients with systemic lupus erythematosus and memory deficits.

Purpose Cognitive dysfunction is common in neuropsychiatric systemic lupus erythematosus (SLE). Memory is a commonly affected cognitive domain. Clinically, however, it is difficult to detect memory deficits. The objective of this study is to evaluate whether normal controls and SLE patients with and without memory deficit differ in terms of white-matter integrity. Methods Twenty SLE patients with ...

Intravenous human immunoglobulin for the treatment of severe longitudinal extensive transverse myelitis associated with systemic lupus erythematous.

A 39-year-old female with systemic lupus erythematous (SLE) presented with fever, headaches and rash and was treated with empiric antibiotics for a presumable meningitis. However, cerebrospinal fluid turned out to be sterile and fever persisted with onset of hyporeflexive paraparesis with sensory loss below D10. Magnetic resonance imaging (MRI) demonstrated intradural-extramedullary hematoma (rela...

Facilitated expansion of Th17 cells in lupus nephritis patients.

The objective of this study was to investigate the mechanisms of Th17 expansion in lupus nephritis (LN) patients, and determine whether it is associated with impaired function of regulatory T-cells (Treg). Major effector subsets of peripheral blood CD4+ T-cells were assessed by flow cytometry in 33 LN patients with different activity of the disease, and 19 healthy controls. Percentage of circulati...

High-sensitive troponin is associated with subclinical imaging biosignature of inflammatory cardiovascular involvement in systemic lupus erythematosus.

Cardiovascular (CV) involvement in patients with systemic lupus erythematosus (SLE) is presumably subclinical for the major part of its evolution. We evaluated the associations between high-sensitive troponin T (hs-TropT), a sensitive marker of myocardial injury, and CV involvement using cardiac magnetic resonance (CMR).

Distinctive lupus panniculitis of scalp with linear alopecia along Blaschko's lines: a review of the literature.

Lupus panniculitis of the scalp (LPS) is a rare and distinctive clinical feature of lupus erythematosus panniculitis (LEP) with linear alopecia along Blaschko's lines. In this study, we investigated clinical features and treatments of LPS by literature review of articles in the English language from PubMed and SCOPUS databases up to April 2018. The following key words, "lupus panniculitis, "lupus ...

Chilblain lupus erythematosus presenting with bilateral hemorrhagic bullae of distal halluces.

Association between miRNA-146a and Polymorphisms of its Target Gene, IRAK1, Regarding Susceptibility to and Clinical Features of Systemic Lupus Erythematous and Multiple Sclerosis.

Single-nucleotide polymorphisms (SNPs) in microRNA-146a (miRNA-146a) can be associated with the development of immune-system dysfunctions.The aim of this work is to correlate SNPs of miRNA-146a and its target gene, IRAK1, with susceptibility, clinical manifestations, and diseases progression in patients with systemic lupus erythematous (SLE) and multiple sclerosis (MS). Genotyping for miRNA-146a (...

mTOR regulates NLRP3 inflammasome activation via reactive oxygen species in murine lupus.

Inflammasomes are protein complexes responsible for the release of IL-1 family cytokines, and they play critical roles in immunity and inflammation. The best-characterized inflammasome, the NOD-like receptor protein 3 (NLRP3) inflammasome, is involved in the development of multiple autoimmune diseases. However, the underlying mechanisms of abnormal NLRP3 inflammasome activation in systemic lupus e...

Factors associated with remission in patients with systemic lupus erythematosus: new insights into a desirable state.

The primary aim of this study was to assess demographic, clinical, and serological factors associated with remission in systemic lupus erythematosus (SLE). A retrospective cohort study was performed. We examined relevant features in patients with SLE with a follow-up of at least 8 years from active disease (SLE Disease Activity Index-2000 [SLEDAI-2K] ≥6). The primary outcome was to assess vario...

Artemisinins-a Promising New Treatment for Systemic Lupus Erythematosus: a Descriptive Review.

Systemic lupus erythematosus (SLE) is a complex, potentially fatal autoimmune disease with no complete cure. Current treatments for SLE are limited by suboptimal efficacy and increased risk of infections and malignancies, and cannot meet the clinical demands of patients with SLE. Artemisinin and its derivatives (artemisinins), a new class of anti-malarial drugs, have recently been reported to have...

Clinically diagnosed urticaria and risk of systemic lupus eythematosus in children: a nationwide population-based case-control study.

Urticaria is one of the most common diseases seen in clinical practice, whereas several reports have proposed that urticaria may have a link with autoimmune disorders. Few studies have examined the clinical association between urticaria with systemic lupus erythematosus (SLE). By conducting a nationwide population-based case-control study in Taiwan, we evaluated the risk of SLE in children with a ...

Area-level Predictors of Medication Nonadherence among U.S. Medicaid Beneficiaries with Lupus: A Multilevel Study.

Adherence to hydroxychloroquine (HCQ) among patients with systemic lupus erythematous (SLE) is suboptimal. Individual-level factors, including younger age and non-white race/ethnicity, have been implicated; contextual factors have not been explored.

Clinical remission and low disease activity have comparable outcomes over 10 years in systemic lupus erythematosus.

We recently showed that low disease activity (LDA), defined as a clinical SLEDAI-2K≤2, maintained for 12 months, confers the same risk for damage accrual as complete remission after two years. The aim of the present study was to assess the validity of these findings in the long term (10 years).

The impact of belimumab and rituximab on health-related quality of life in patients with systemic lupus erythematosus.

Accumulating evidence supports an impaired health-related quality of life (HRQoL) in patients with systemic lupus erythematosus (SLE). We investigated the effects of two biologic treatments on SLE patients' HRQoL.

The Incidence and Prevalence of Adult Primary Sjögren's Syndrome in New York County.

Extant epidemiologic data of primary Sjögren's Syndrome (pSS) remains limited, particularly for racial/ethnic populations in the United States (US). The Manhattan Lupus Surveillance Program (MLSP), a population-based retrospective registry of cases with Systemic Lupus Erythematosus and related diseases including pSS in Manhattan, was used to provide estimates of the incidence and prevalence of pS...

Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort.

The spectrum of antinuclear antibodies (ANA) is changing to include both nuclear staining as well as cytoplasmic and mitotic cell patterns (CMPs) and accordingly a change in terminology to anti-cellular antibodies. This study examined the prevalence of indirect immunofluorescence (IIF) anti-cellular antibody staining using the Systemic Lupus International Collaborating Clinics inception cohort.

Partial small intestinal resection for successful surgical management of refractory protein-losing gastroenteropathy in systemic lupus erythematosus: A case report and literature review.

Although systemic lupus erythematosus (SLE) can be complicated by various gastrointestinal tract diseases, it is rarely associated with lupus enteritis and protein-losing enteropathy (PLE). We report here the successful surgical treatment of lupus enteritis and therapy-resistant and refractory PLE in a patient with SLE. We also provide a review of relevant literature.

Lessons learned from the failure of several recent trials with biologic treatment in systemic lupus erythematosus.

Treatment of systemic lupus erythematosus (SLE) represents a challenge due to variable disease manifestations, clinical course and outcome. Long-term outcome in SLE remain unsatisfactory and a search for new therapeutic options is definitely warranted. Despite expectations, most clinical trials performed in SLE and lupus nephritis in the last decade did not reach primary outcome, and the only drug...

Quick Search


review and buy Lupus market research data and corporate reports here